InvestorsHub Logo
Followers 78
Posts 3549
Boards Moderated 0
Alias Born 01/17/2003

Re: Nemesis18 post# 690701

Saturday, 05/11/2024 8:29:23 PM

Saturday, May 11, 2024 8:29:23 PM

Post# of 694338
13% success rate is nonsense, a lie. Please just stop it. You get worked up over your laser-like focus on the wrong things. Like citing an 87% failure rate because only 13% of patients survive 5 years. First, all the patients under the glioblastoma death sentence are not throw-aways if they don't reach 5-year survival. Patients facing a 12-month death sentence getting another 12-24 months or even 6-12 months of high QoL with their families is not a failure in the least. Don't be stone-hearted and oblivious!

Furthermore, most recent studies have shown as many as 50% or more patients surviving more than 5 years with dc-vaxl in combination with other treatments. This is not part of the ph3 trial data but it's well known fact Fortunately, the RAs don't think like you! Your '87% failure rate' is a very big lie that reveals where you are coming from, and it's nowhere nice.

Second, NWBO's balance sheet is far from fantastic, but they have survived for several decades with no product income and there is no sign that they cannot deliver the treatment at a reasonable price per the market for similar treatments and become quite profitable just from the GBM patient population of the UK. Only the most closed-minded bean-counter would insist otherwise.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News